Charles Schwab’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Charles Schwab’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-626	Closed	-$7.38K	–	3727
2023 Q1	$7.38K	Hold	626	–	–	﹤0.01%	3543
2022 Q4	$9.02K	Hold	626	–	–	﹤0.01%	3536
2022 Q3	$32K	Sell	626 -460	-42%	-$32K	﹤0.01%	3420
2022 Q2	$93K	Sell	1,086 -746	-41%	-$63.8K	﹤0.01%	3295
2022 Q1	$277K	Sell	1,832 -92	-5%	-$21.2K	﹤0.01%	3235
2021 Q4	$576K	Buy	1,924 +138	+8%	+$52.9K	﹤0.01%	3101
2021 Q3	$697K	Buy	1,786 +140	+9%	+$59.7K	﹤0.01%	3024
2021 Q2	$695K	Buy	+1,646	New	+$712K	﹤0.01%	3057

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Charles Schwab's FNCH Position: Q2 2023 in Review

Charles Schwab sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 626 shares — an estimated $7.38K sold.

Charles Schwab first reported a position in FNCH in Q2 2021 and held it in 8 quarters. The position peaked at $697K in Q3 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

Charles Schwab reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Charles Schwab sold 626 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $7.38K.
Charles Schwab first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Charles Schwab's Finch Therapeutics Group, Inc. Common Stock position peaked at $697K in Q3 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.